Oliver Wildner

2.5k total citations
61 papers, 2.0k citations indexed

About

Oliver Wildner is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Oliver Wildner has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Genetics, 29 papers in Molecular Biology and 27 papers in Oncology. Recurrent topics in Oliver Wildner's work include Virus-based gene therapy research (47 papers), CAR-T cell therapy research (26 papers) and Viral Infectious Diseases and Gene Expression in Insects (16 papers). Oliver Wildner is often cited by papers focused on Virus-based gene therapy research (47 papers), CAR-T cell therapy research (26 papers) and Viral Infectious Diseases and Gene Expression in Insects (16 papers). Oliver Wildner collaborates with scholars based in Germany, United States and Japan. Oliver Wildner's co-authors include Dennis Hoffmann, R. Michael Blaese, John C. Morris, Klaus Überla, Wibke Bayer, Christian Jogler, W. Jay Ramsey, Thomas Grünwald, Nicholas N. Vahanian and Harry Ford and has published in prestigious journals such as Circulation, PLoS ONE and Cancer Research.

In The Last Decade

Oliver Wildner

61 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oliver Wildner Germany 25 1.1k 1.0k 663 392 365 61 2.0k
Christine L. White United States 24 691 0.6× 722 0.7× 455 0.7× 349 0.9× 475 1.3× 46 1.9k
Laurent Humeau United States 26 822 0.7× 1.1k 1.1× 429 0.6× 250 0.6× 542 1.5× 64 2.2k
J C Byrne United States 11 619 0.5× 872 0.9× 614 0.9× 887 2.3× 317 0.9× 13 2.0k
David A. Ornelles United States 31 1.9k 1.6× 1.8k 1.7× 903 1.4× 341 0.9× 414 1.1× 72 3.0k
Nelson C. Di Paolo United States 15 753 0.7× 888 0.9× 461 0.7× 258 0.7× 927 2.5× 20 2.1k
Natalie A. Hutnick United States 14 441 0.4× 531 0.5× 575 0.9× 303 0.8× 796 2.2× 26 1.7k
Simon D. Scott United Kingdom 24 516 0.5× 509 0.5× 498 0.8× 721 1.8× 154 0.4× 67 1.9k
Arjen Q. Bakker Netherlands 25 243 0.2× 707 0.7× 531 0.8× 367 0.9× 1.3k 3.6× 49 2.7k
Fernando Esquivel‐Guadarrama Mexico 21 220 0.2× 509 0.5× 416 0.6× 357 0.9× 1.1k 3.1× 49 1.8k
Ianko Iankov United States 22 865 0.8× 469 0.5× 501 0.8× 473 1.2× 252 0.7× 54 1.6k

Countries citing papers authored by Oliver Wildner

Since Specialization
Citations

This map shows the geographic impact of Oliver Wildner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Wildner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Wildner more than expected).

Fields of papers citing papers by Oliver Wildner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Wildner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Wildner. The network helps show where Oliver Wildner may publish in the future.

Co-authorship network of co-authors of Oliver Wildner

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Wildner. A scholar is included among the top collaborators of Oliver Wildner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Wildner. Oliver Wildner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wildner, Oliver, et al.. (2013). Interleukin-Encoding Adenoviral Vectors as Genetic Adjuvant for Vaccination against Retroviral Infection. PLoS ONE. 8(12). e82528–e82528. 13 indexed citations
2.
Kosinska, Anna D., Ejuan Zhang, Jia Liu, et al.. (2013). Combination of DNA Prime – Adenovirus Boost Immunization with Entecavir Elicits Sustained Control of Chronic Hepatitis B in the Woodchuck Model. PLoS Pathogens. 9(6). e1003391–e1003391. 83 indexed citations
3.
Tenbusch, Matthias, et al.. (2013). Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice. Virology Journal. 10(1). 108–108. 16 indexed citations
4.
Strauss, Robert, Pavel Sova, Ying Liu, et al.. (2009). Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses. Cancer Research. 69(12). 5115–5125. 57 indexed citations
5.
Potthoff, Anja, Ghulam Nabi, Dennis Hoffmann, et al.. (2009). Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines. Vaccine. 27(21). 2768–2774. 11 indexed citations
6.
Hesse, Andrea, Wibke Bayer, Christel Herold‐Mende, et al.. (2009). Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. Virology. 395(2). 243–254. 9 indexed citations
7.
Temchura, Vladimir, Matthias Tenbusch, Godwin Nchinda, et al.. (2008). Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus. Vaccine. 26(29-30). 3662–3672. 72 indexed citations
8.
Hoffmann, Dennis, Bernhard Meyer, & Oliver Wildner. (2007). Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. The Journal of Gene Medicine. 9(9). 764–778. 34 indexed citations
9.
Steel, Jason C., Brian J. Morrison, Poonam Mannan, et al.. (2007). Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus. Virology. 369(1). 131–142. 23 indexed citations
10.
11.
Steinstraesser, Lars, Bettina Tippler, Evert N. Lamme, et al.. (2005). Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2(1). 2–2. 89 indexed citations
12.
Wildner, Oliver, Dennis Hoffmann, Christian Jogler, & Klaus Überla. (2003). Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Therapy. 10(10). 791–802. 32 indexed citations
13.
Wildner, Oliver. (2001). Oncolytic viruses as therapeutic agents. Annals of Medicine. 33(5). 291–304. 20 indexed citations
14.
Okada, Takashi, Mala M. Shah, Oliver Wildner, et al.. (2001). AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Therapy. 8(17). 1315–1322. 25 indexed citations
15.
Wildner, Oliver, et al.. (2000). The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.. PubMed. 60(15). 4167–74. 68 indexed citations
16.
Morris, John C. & Oliver Wildner. (2000). Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk. Molecular Therapy. 1(1). 56–62. 64 indexed citations
17.
Wildner, Oliver. (1999). In situuse of suicide genes for therapy of brain tumours. Annals of Medicine. 31(6). 421–429. 28 indexed citations
18.
Morris, John C., Renaud Touraine, Oliver Wildner, & R. Michael Blaese. (1999). 18 Suicide Genes: Gene Therapy Applications Using Enzyme/Prodrug Strategies. Cold Spring Harbor Monograph Archive. 36. 477–526. 4 indexed citations
19.
Wildner, Oliver, John C. Morris, Nicholas N. Vahanian, et al.. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Therapy. 6(1). 57–62. 141 indexed citations
20.
Wildner, Oliver, et al.. (1992). Increased expression of ICAM‐1, E‐selectin, and VCAM‐1 by cultured human endothelial cells upon exposure to haptens. Experimental Dermatology. 1(4). 191–198. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine L. White Breakdown of academic impact, for papers by Laurent Humeau Breakdown of academic impact, for papers by J C Byrne Breakdown of academic impact, for papers by David A. Ornelles Breakdown of academic impact, for papers by Nelson C. Di Paolo Breakdown of academic impact, for papers by Natalie A. Hutnick Breakdown of academic impact, for papers by Simon D. Scott Breakdown of academic impact, for papers by Arjen Q. Bakker Breakdown of academic impact, for papers by Fernando Esquivel‐Guadarrama Breakdown of academic impact, for papers by Ianko Iankov
Rankless by CCL
2026